Who and when should we screen for prostate cancer? Interviews with key opinion leaders

Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial. In this Q & A, Guest Editors for BMC Medicine’s ‘Spotlight on Prostate Cancer’ article collection, Sigrid Carlsson and Andrew Vickers, invite some of the world’s key opinion leaders to discuss who, and when,...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlsson, Sigrid, Leapman, Michael, Carroll, Peter, Schröder, Fritz, Albertsen, Peter C., Ilic, Dragan, Barry, Michael, Frosch, Dominick L., Vickers, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Forum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662021/
https://www.ncbi.nlm.nih.gov/pubmed/26612204
http://dx.doi.org/10.1186/s12916-015-0526-x
_version_ 1782403098790068224
author Carlsson, Sigrid
Leapman, Michael
Carroll, Peter
Schröder, Fritz
Albertsen, Peter C.
Ilic, Dragan
Barry, Michael
Frosch, Dominick L.
Vickers, Andrew
author_facet Carlsson, Sigrid
Leapman, Michael
Carroll, Peter
Schröder, Fritz
Albertsen, Peter C.
Ilic, Dragan
Barry, Michael
Frosch, Dominick L.
Vickers, Andrew
author_sort Carlsson, Sigrid
collection PubMed
description Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial. In this Q & A, Guest Editors for BMC Medicine’s ‘Spotlight on Prostate Cancer’ article collection, Sigrid Carlsson and Andrew Vickers, invite some of the world’s key opinion leaders to discuss who, and when, to screen for prostate cancer. In response to the points of view from the invited experts, the Guest Editors summarize the experts’ views and give their own personal opinions on PSA screening.
format Online
Article
Text
id pubmed-4662021
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46620212015-11-28 Who and when should we screen for prostate cancer? Interviews with key opinion leaders Carlsson, Sigrid Leapman, Michael Carroll, Peter Schröder, Fritz Albertsen, Peter C. Ilic, Dragan Barry, Michael Frosch, Dominick L. Vickers, Andrew BMC Med Forum Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial. In this Q & A, Guest Editors for BMC Medicine’s ‘Spotlight on Prostate Cancer’ article collection, Sigrid Carlsson and Andrew Vickers, invite some of the world’s key opinion leaders to discuss who, and when, to screen for prostate cancer. In response to the points of view from the invited experts, the Guest Editors summarize the experts’ views and give their own personal opinions on PSA screening. BioMed Central 2015-11-27 /pmc/articles/PMC4662021/ /pubmed/26612204 http://dx.doi.org/10.1186/s12916-015-0526-x Text en © Carlsson et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Forum
Carlsson, Sigrid
Leapman, Michael
Carroll, Peter
Schröder, Fritz
Albertsen, Peter C.
Ilic, Dragan
Barry, Michael
Frosch, Dominick L.
Vickers, Andrew
Who and when should we screen for prostate cancer? Interviews with key opinion leaders
title Who and when should we screen for prostate cancer? Interviews with key opinion leaders
title_full Who and when should we screen for prostate cancer? Interviews with key opinion leaders
title_fullStr Who and when should we screen for prostate cancer? Interviews with key opinion leaders
title_full_unstemmed Who and when should we screen for prostate cancer? Interviews with key opinion leaders
title_short Who and when should we screen for prostate cancer? Interviews with key opinion leaders
title_sort who and when should we screen for prostate cancer? interviews with key opinion leaders
topic Forum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662021/
https://www.ncbi.nlm.nih.gov/pubmed/26612204
http://dx.doi.org/10.1186/s12916-015-0526-x
work_keys_str_mv AT carlssonsigrid whoandwhenshouldwescreenforprostatecancerinterviewswithkeyopinionleaders
AT leapmanmichael whoandwhenshouldwescreenforprostatecancerinterviewswithkeyopinionleaders
AT carrollpeter whoandwhenshouldwescreenforprostatecancerinterviewswithkeyopinionleaders
AT schroderfritz whoandwhenshouldwescreenforprostatecancerinterviewswithkeyopinionleaders
AT albertsenpeterc whoandwhenshouldwescreenforprostatecancerinterviewswithkeyopinionleaders
AT ilicdragan whoandwhenshouldwescreenforprostatecancerinterviewswithkeyopinionleaders
AT barrymichael whoandwhenshouldwescreenforprostatecancerinterviewswithkeyopinionleaders
AT froschdominickl whoandwhenshouldwescreenforprostatecancerinterviewswithkeyopinionleaders
AT vickersandrew whoandwhenshouldwescreenforprostatecancerinterviewswithkeyopinionleaders

Ejemplares similares